MA49903A - Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 - Google Patents

Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3

Info

Publication number
MA49903A
MA49903A MA049903A MA49903A MA49903A MA 49903 A MA49903 A MA 49903A MA 049903 A MA049903 A MA 049903A MA 49903 A MA49903 A MA 49903A MA 49903 A MA49903 A MA 49903A
Authority
MA
Morocco
Prior art keywords
sulphonylurides
sulphonylthiourides
nlrp3 inhibitors
nlrp3
inhibitors
Prior art date
Application number
MA049903A
Other languages
English (en)
Inventor
Thomas Alanine
Arregui Jokin Carrillo
Matthew Cooper
Angus Macleod
David Miller
Stuart Onions
Jonathan Shannon
Stephen St-Gallay
Ian Strutt
Stephen Thom
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713082.4A external-priority patent/GB201713082D0/en
Priority claimed from GBGB1718563.8A external-priority patent/GB201718563D0/en
Priority claimed from GBGB1721731.6A external-priority patent/GB201721731D0/en
Priority claimed from GBGB1721726.6A external-priority patent/GB201721726D0/en
Priority claimed from GBGB1810983.5A external-priority patent/GB201810983D0/en
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MA49903A publication Critical patent/MA49903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA049903A 2017-08-15 2018-08-15 Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 MA49903A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1713082.4A GB201713082D0 (en) 2017-08-15 2017-08-15 Novel compounds
GBGB1718563.8A GB201718563D0 (en) 2017-11-09 2017-11-09 Novel compounds
GBGB1721731.6A GB201721731D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1721726.6A GB201721726D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1810983.5A GB201810983D0 (en) 2018-07-04 2018-07-04 Novel compounds

Publications (1)

Publication Number Publication Date
MA49903A true MA49903A (fr) 2020-06-24

Family

ID=63364050

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049903A MA49903A (fr) 2017-08-15 2018-08-15 Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3

Country Status (18)

Country Link
US (2) US11613542B2 (fr)
EP (2) EP3668599A1 (fr)
JP (1) JP2020531453A (fr)
KR (1) KR20200041919A (fr)
CN (2) CN111093773A (fr)
AU (1) AU2018317798A1 (fr)
BR (1) BR112020003014A2 (fr)
CA (1) CA3071150A1 (fr)
CL (1) CL2020000367A1 (fr)
IL (1) IL272557A (fr)
MA (1) MA49903A (fr)
MX (1) MX2020001776A (fr)
PE (1) PE20200758A1 (fr)
RU (1) RU2020110219A (fr)
SG (1) SG11202001166RA (fr)
TW (1) TW201910316A (fr)
UY (1) UY37847A (fr)
WO (2) WO2019034690A1 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
CN109071454B (zh) 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
CA3056563C (fr) 2017-03-17 2023-03-14 Meiji Seika Pharma Co., Ltd. Agent de lutte contre les maladies des plantes
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668861A1 (fr) * 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
EP3668862A1 (fr) * 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
KR20200087759A (ko) * 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
US12221434B2 (en) * 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
EP3759078A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759077A1 (fr) * 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
SG11202012159TA (en) 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
EP3823974A1 (fr) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN114641466B (zh) 2019-06-12 2025-09-30 诺瑟拉有限公司 磺酰脲衍生物及其用途
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
AU2020312800B2 (en) 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
JP7595642B2 (ja) 2019-07-17 2024-12-06 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
EP4013761A1 (fr) 2019-08-16 2022-06-22 Inflazome Limited Dérivés de sulfonylurée macrocycliques utiles en tant qu'inhibiteurs de nlrp3
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
CN117105890A (zh) * 2019-11-12 2023-11-24 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
CN114829345A (zh) * 2019-12-27 2022-07-29 日本烟草产业株式会社 酰基磺酰胺化合物及其医药用途
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物
EP4110058A4 (fr) * 2020-02-28 2024-03-20 Zydus Lifesciences Limited Nouveaux dérivés de sulfonylurées et de sulfoximineurées substitués
CN111217718B (zh) * 2020-03-11 2023-06-16 安徽东健化工科技有限公司 无硫2-溴-4-氟乙酰苯胺合成方法
KR20220154165A (ko) 2020-03-16 2022-11-21 조마젠 바이오사이언시즈 엘티디 Nlrp3 조절제
CN111362835B (zh) * 2020-04-20 2022-08-30 苏州科晟通新材料科技有限公司 一种具有阻燃和抗水解功能的碳化二亚胺化合物及其制备方法
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
EP4161933A1 (fr) * 2020-06-08 2023-04-12 Halia Therapeutics, Inc. Inhibiteurs de la kinase nek7
US12428391B2 (en) 2020-06-11 2025-09-30 Cisen Pharmaceutical Co., Ltd Dimethylsulfoximine derivative
MX2022014709A (es) 2020-06-19 2022-12-16 Ac Immune Sa Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3).
CN112022862B (zh) * 2020-08-21 2025-07-18 华东理工大学 磺酰脲类药物的抗衰老新用途
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022135567A1 (fr) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 Composé contenant de la pyridazine et son utilisation médicinale
JP7825294B2 (ja) * 2021-02-10 2026-03-06 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
JP2024538602A (ja) * 2021-09-29 2024-10-23 ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド インターロイキン－１活性の阻害剤としての新規の置換スルホニル尿素化合物
TW202333678A (zh) * 2021-12-22 2023-09-01 大陸商瑞石生物醫藥有限公司 一種磺醯脲類化合物
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CA3261365A1 (fr) 2022-07-28 2024-02-01 Ac Immune Sa Nouveaux composés
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
WO2025133307A1 (fr) 2023-12-22 2025-06-26 Ac Immune Sa Modulateurs hétérocycliques de la voie de l'inflammasome nlrp3
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1
WO2025153624A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025153625A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025163069A1 (fr) 2024-01-31 2025-08-07 Ac Immune Sa Nouveaux composés
WO2026057747A1 (fr) 2024-09-11 2026-03-19 Ac Immune Sa Utilisation thérapeutique de composés inhibiteurs de la voie de l'inflammasome nlrp3

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
NL129208C (fr) 1965-07-14
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
DE3479213D1 (en) 1983-05-16 1989-09-07 Ciba Geigy Ag Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
JPH0720958B2 (ja) * 1985-01-18 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホンアミド誘導体、製法および除草剤
FI855180A7 (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyratsolisulfonamidijohdannainen, menetelmä sen valmistamiseksi ja sitä sisältävä rikkaruohomyrkky.
CA1231336A (fr) 1985-05-30 1988-01-12 George Levitt Sulfonamides herbicides
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
EP0262096B1 (fr) 1986-09-26 1992-01-02 Ciba-Geigy Ag Aminopyrazinones et aminotriazinones
US4802908A (en) 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
CA2074163A1 (fr) 1990-01-22 1991-07-23 William Thomas Zimmerman Herbicides a base de sulfonyluree
NZ238911A (en) 1990-07-17 1993-10-26 Lilly Co Eli Furyl, pyrrolyl and thienyl sulphonyl urea derivatives, pharmaceutical compositions and intermediates therefor
WO1992004319A1 (fr) 1990-08-29 1992-03-19 E.I. Du Pont De Nemours And Company Pyrrolesulfonylurees herbicides
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
WO1993004045A1 (fr) 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii sur ses recepteurs
AU2494792A (en) 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH06199054A (ja) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd 熱転写シート
JPH06199053A (ja) 1992-12-28 1994-07-19 Sankyo Kagaku Kk 感熱転写記録用色素
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
AU7007696A (en) 1995-09-22 1997-04-09 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
AU1735497A (en) 1996-02-26 1997-09-10 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
SI0964849T1 (en) 1997-01-29 2003-10-31 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
AU723895B2 (en) 1997-01-29 2000-09-07 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
EP0987552A3 (fr) 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
DE60021254T2 (de) 1999-03-15 2006-04-20 AXYS Pharmaceuticals, Inc., South San Francisco N-cyanomethylamide als protease inhibitoren
WO2001019390A1 (fr) * 1999-09-14 2001-03-22 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (fr) 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Inhibiteurs des recepteurs d'adp des plaquettes
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (fr) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
JP2004536063A (ja) 2001-05-18 2004-12-02 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 医薬の製造における組み合わせたｎｅｐ／ｍｐ−抑制活性を有する化合物の使用
FI110677B (fi) 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1487457A1 (fr) 2001-11-30 2004-12-22 Pfizer Products Inc. Combinaison d'un inhibiteur d'il-1/18 avec un inhibiteur de tnf pour le traitement d'inflammations
US7138530B2 (en) 2002-05-28 2006-11-21 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
KR20060113699A (ko) 2003-10-03 2006-11-02 포톨라 파마슈티컬스, 인코포레이티드 치환된 이소퀴놀리논
ES2334795T3 (es) 2003-10-03 2010-03-16 Portola Pharmaceuticals, Inc. Sulfonilureas 2,4-dioxo-3-quinazolinilarilo.
EP1812429A4 (fr) 2004-09-29 2010-07-21 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-ones substitues
AR052900A1 (es) * 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
MY183861A (en) 2010-03-05 2021-03-17 Kyowa Hakko Kirin Co Ltd Pyrazolopyrimidine derivative
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
PL221813B1 (pl) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
KR102350357B1 (ko) * 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
CN104513239B (zh) 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
KR102727059B1 (ko) 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
US10688077B2 (en) 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
EP3394080B1 (fr) 2015-12-23 2023-06-07 The University Of British Columbia Promédicaments liés à des lipides
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
CN109071454B (zh) 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
ES2940611T3 (es) * 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
EP3272739A1 (fr) 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
CA3047336A1 (fr) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951B8 (fr) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Nouveaux composés de sulfoximine substitués
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN111094242B (zh) 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3668861A1 (fr) * 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034693A1 (fr) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
EP3668862A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US11518739B2 (en) * 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
EP3697758B1 (fr) 2017-10-17 2022-07-06 Novartis AG Sulfonamides et compositions associées pour le traitement d'états pathologiques associés à une activité de nlrp
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
WO2019092172A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
CN110151749B (zh) 2018-02-13 2022-04-19 中国科学技术大学 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
EP3759078A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
WO2019166624A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
EP3759077A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
SG11202012159TA (en) 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CR20210235A (es) 2018-11-13 2021-06-30 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN109432078B (zh) 2018-12-04 2020-09-01 南华大学 一种化合物在制备预防或治疗电离辐射所致认知障碍药物中的应用
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
CN114555609A (zh) 2019-08-16 2022-05-27 英夫拉索姆有限公司 用作nlrp3抑制剂的大环磺酰胺衍生物
EP4013761A1 (fr) 2019-08-16 2022-06-22 Inflazome Limited Dérivés de sulfonylurée macrocycliques utiles en tant qu'inhibiteurs de nlrp3
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物

Also Published As

Publication number Publication date
SG11202001166RA (en) 2020-03-30
KR20200041919A (ko) 2020-04-22
RU2020110219A (ru) 2021-09-17
WO2019034690A1 (fr) 2019-02-21
CL2020000367A1 (es) 2020-08-28
EP3837242A1 (fr) 2021-06-23
UY37847A (es) 2019-03-29
EP3668599A1 (fr) 2020-06-24
AU2018317798A1 (en) 2020-02-13
CN111093773A (zh) 2020-05-01
US20210130359A1 (en) 2021-05-06
JP2020531453A (ja) 2020-11-05
CA3071150A1 (fr) 2019-02-21
US11613542B2 (en) 2023-03-28
WO2020035465A1 (fr) 2020-02-20
PE20200758A1 (es) 2020-07-27
TW201910316A (zh) 2019-03-16
MX2020001776A (es) 2020-03-24
BR112020003014A2 (pt) 2020-07-28
IL272557A (en) 2020-03-31
RU2020110219A3 (fr) 2022-02-15
US20210163412A1 (en) 2021-06-03
CN112789264A (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
LT3661921T (lt) Selektyvūs nlrp3 inflamasomos inhibitoriai
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
PL3481852T3 (pl) Nowa neurotoksyna botulinowa i jej pochodne
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3444254A4 (fr) Dérivé de pyridinopyrimidinone substitué hétérocyclique en tant qu'inhibiteur de cdk et son utilisation
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
PT3606519T (pt) Compostos de inibidor de ask1 e utilizações dos mesmos
MA46746A (fr) Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
EP3250367A4 (fr) Étalonnage d'agent